The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Regeneron's Evkeeza Achieves Landmark FDA Approval, Extending Life-Saving Treatment to Youngest HoFH Patients

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers

A Beacon of Hope: Regeneron's Pozelimab Shines in Ultra-Rare Genetic Disorder Study

A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle

First RSV shots, groundbreaking gene therapy among 2024 drugs to watch

RBC ups Regeneron to outperform; cites Eylea patent win, Dupi sales